
The signs of cancer you should be checking for every three weeks
According to a new NHS survey of 2,000 people, only 39 per cent of Brits examine our bodies regularly, with many of us far more likely to check our bank balance, the weather forecast and what's coming up on TV during the same timeframe.
But complacency can lead to deadly consequences: Dr Richard Lee, a champion for early cancer diagnosis at The Royal Marsden Hospital, says delays in people mentioning concerns to their GP are one of the primary causes for early-stage cancers getting missed. 'Many cancers do present with symptoms,' he says. 'The earlier that a cancer is diagnosed, treatments are easier [to tolerate] and treatment success is more likely.'
While the NHS offers national screening programmes for breast, bowel and cervical cancers, and is in the process of expanding lung-cancer screening, such programmes only cover a proportion of cancers, making self-checking vitally important, especially as more cancers are being diagnosed under the age of 50.
According to the American Cancer Society, one general feature of many cancers is sudden or unexplained weight loss – for example, losing 5 per cent of your body weight over six to 12 months when you're not intentionally trying to lose weight.
'Cancer can be associated with reduced appetite and weight loss, essentially due to the metabolic effects of the cancer on the body,' says Dr Lee. 'It's partly because there's something there that's growing and it's also a feature of cancer which makes muscles weak while the metabolism is increasing; you've got this inflammation and all these things combined make it hard to keep your weight steady.'
Of course, this doesn't always occur, but certain cancers can be picked up through regular self-checking. Here are some of the most notable symptoms to look out for.
Testicular cancer
Warning signs: Lump or swelling
Testicular cancer usually presents through a testicular lump or swelling or sudden pain in the testicles. There could be a perfectly benign cause for lumps and swelling, but if you're experiencing these symptoms, Dr Robert Stevenson, Consultant Clinical Oncologist at The Harborne Hospital, says it's critical to be examined by a doctor quickly.
'A lump can be a cyst at the back of the testicle, or a varicocele, which is a collection of [enlarged] veins,' he says. 'Incidentally, this can also be an early sign of kidney cancer and that would be looked into too.'
If caught early, the cure rates for testicular cancer are very high, while patients will also avoid more debilitating treatments such as multiple rounds of chemotherapy and radiotherapy. 'If it's stage one – so, still confined to the testicle – you may just need the testicle removed, maybe a bit of chemotherapy, and that's it,' says Dr Stevenson.
What to do?
If you feel any sort of lump, swelling or unusual pain in the testicle region, this should prompt a visit to the doctor. An ultrasound scan will be required to diagnose whether it's cause for alarm or benign.
Survival rate if caught early: 99 per cent.
Leukaemia
Warning signs: Unexplained bleeding or bruising
In adults, leukaemia can be one of the more aggressive and difficult to treat cancers, but, when detected early, oncologists say that there are far more options, from chemotherapy to newer immunotherapies and stem-cell transplants.
With leukaemia being a blood cancer, Dr Premini Mahendra, Consultant Haemato-Oncologist at The Harborne Hospital, says that a major warning sign is unexplained bleeding or bruising on the body.
'Patients also sometimes feel unusually fatigued, they're getting recurrent infections, or they have unexplained shortness of breath,' she says.
What to do?
Consult your GP. To rule out leukaemia, Dr Mahendra says you will be given a simple blood test. 'There are lots of other possible explanations, but a full blood cell count, which is one of the cheapest tests to do, will indicate if leukaemia could be responsible or not,' she adds.
Survival rate if caught early: 67 per cent.
Breast cancer
Warning sign: Lumps
According to the NHS, visible signs of breast cancer typically present as hard, irregular, painless lumps that feel slightly different from the surrounding breast tissue, sometimes accompanied by the formation of dimples or changes in the nipple's appearance.
While the disease is most common in women over the age of 50, it can occur in younger women and, as a result, the charity Breast Cancer Ireland has long promoted self-checking as crucial. 'It's important to check yourself regularly so you know what your baseline is, which helps you spot any unusual changes,' says Aisling Hurley, the charity's CEO.
What to do?
While women aged 50-70 are offered mammograms as part of the NHS screening service, you can get a free mammogram earlier if you detect a lump or a concerning sign. Newer, more effective screening tools are also in the pipeline, with Cancer Research UK-funded researchers developing an enhanced mammogram to detect cancer in women with extra-dense breasts (which can make it more difficult to spot the signs of cancer in the first place).
Survival rate if caught early: 95 per cent.
Lymphoma
Warning sign: Swelling
As a cancer that affects the lymphatic system (the complex network of vessels and glands that represent a vital part of the immune system), early signs of lymphoma typically present as painless swellings that form around the body's lymph nodes.
'You can get these swellings which people feel most commonly in the neck, the armpit and the groin,' says Dr Mahendra. 'You can also get swollen glands after a viral infection, but those tend to be tender and painful, while it could be lymphoma if it's painless and it has persisted for more than two weeks.'
What to do?
There isn't a blood test for lymphoma, but, if concerned, specialists will carry out a biopsy of the swollen lymph gland to come to a definitive diagnosis.
Again, the key is to seek medical attention as soon as possible. 'You'd be surprised at how many people sometimes just ignore an unexplained swelling, and only present [themselves] at a much later stage with significant weight loss and enlarged lymph glands, as an emergency patient,' adds Dr Mahendra.
Survival rate if caught early: 84-95 per cent.
Bladder cancer
Warning sign: blood in the urine
Blood in urine is known to be a potential sign of prostate cancer (symptoms of which present mainly in late-stage cancer), but it could also indicate the presence of a bladder tumour. According to Dr Stevenson, this is because the vast majority of bladder cancers arise from cells in the lining of the bladder.
'Bleeding, a more frequent need to urinate, pain when urinating and recurrent infections are signs of bladder cancer,' he says.
What to do?
If bladder cancer can be detected before it has penetrated the bladder muscle layer, it is far easier to treat and send into remission. Doctors will likely recommend a flexible cystoscopy – a test in which a fibre-optic tube is used to directly examine the bladder lining.
Survival rate if caught early: 80 per cent.
6. Skin cancer
Warning sign: Irregular, unhealing moles
Knowing whether a new spot or discolouration on the skin is just a standard mole or something more sinister is a common challenge and, to assist, skin cancer experts commonly refer to the so-called ABCD rule – where A stands for Asymmetry, B for Border Irregularity, C for Colour and D for Diameter.
'Essentially, you're looking for anything that's changing; which doesn't really look as it did previously,' says Dr Lee. 'So, either a new mole, an existing mole which is now bleeding or looking more lumpy than before, or looking more irregular. Or a sore that isn't healing, is very painful or seems to be spreading.'
Because skin cancers can sometimes emerge in parts of the body where it isn't so easy to examine, such as the back, shoulders or backs of legs, Dr Lee advises asking for help from a partner or family member in self-checking.
What to do?
If concerned, consult your GP or a dermatologist. Skin cancers will be diagnosed through a combination of visual inspection, examination using a magnifying tool and, finally, a biopsy.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mail
6 minutes ago
- Daily Mail
Shower gel advert banned for depicting black skin as 'problematic' and white skin as 'superior' by advertising watchdog
A shower gel advert has been banned for depicting black skin as 'problematic' and white skin as 'superior', the advertising watchdog has said. The Advertising Standards Authority (ASA) banned the ad after investigating complaints that it perpetuated a 'negative and offensive racial stereotype'. The Sanex shower gel ad, broadcast in June, depicted a black woman with red scratch marks and another covered with a cracked clay-like material. Over this, a voiceover said: 'To those who might scratch day and night. To those whose skin will feel dried out even by water.' Over scenes of a white woman the ad stated: 'Try to take a shower with the new Sanex skin therapy and its patented amino acid complex. For 24 hour hydration feel.' The ad ended with on-screen text and the voiceover adding: 'Relief could be as simple as a shower.' Colgate-Palmolive, which owns the Sanex brand, argued the depiction of diverse models in the ad was shown in a 'before and after' scenario to demonstrate their product was suitable for all, rather than as a comparison based on race or ethnicity. On that basis, it believed the ad did not perpetuate negative racial stereotypes and was not likely to cause serious or widespread offence. Clearcast, which approves or rejects ads for television broadcast, said the ad did not perpetuate negative racial stereotypes and instead demonstrated the product's inclusivity. The agency said one model with darker skin was depicted in a 'stylised and unrealistic way' to demonstrate dryness, but her skin tone was otherwise not a focal point. However the ASA said the use of different skin colours created a juxtaposition of black skin shown as itchy and dry in the 'before' scenes, and white skin shown as smoother in the 'after' scenes. The watchdog said: 'The ad was therefore structured in such a way that it was the black skin, depicted in association with itchy and dry skin, which was shown to be problematic and uncomfortable, whereas the white skin, depicted as smoother and clean after using the product, was shown successfully changed and resolved. 'We considered that could be interpreted as suggesting that white skin was superior to black skin.' The ASA added: 'Although we understood that this message was not the one intended and might appear coincidental or pass unnoticed by some viewers, we considered that the ad was likely to reinforce the negative and offensive racial stereotype that black skin was problematic and that white skin was superior. 'We concluded that the ad included a racial stereotype and was therefore likely to cause serious offence.' Colgate-Palmolive was approached for comment.


The Independent
7 minutes ago
- The Independent
Major brand has advert banned for suggesting black skin is ‘problematic'
A Sanex shower gel television advertisement has been banned by the Advertising Standards Authority (ASA) for reinforcing an offensive racial stereotype. The watchdog ruled the ad, which suggested black skin was "problematic" and white skin "superior", must not air again. This followed two complaints that it perpetuated negative stereotypes about darker skin tones. The ad, seen in June, included a voiceover that said: 'To those who might scratch day and night. To those whose skin will feel dried out even by water,' alongside scenes of a black woman with red scratch marks and another covered with a cracked clay-like material. Alongside scenes of a white woman taking a shower with the product, the ad then stated: 'Try to take a shower with the new Sanex skin therapy and its patented amino acid complex. For 24 hour hydration feel.' The ad ended with on-screen text and the voiceover stating: 'Relief could be as simple as a shower.' Colgate-Palmolive, which owns the Sanex brand, said the depiction of diverse models in the ad, either experiencing skin discomfort or post-product relief, was shown in a 'before and after' scenario to show their product was suitable and effective for all, rather than as a comparison based on race or ethnicity. On that basis, it believed the ad did not perpetuate negative racial stereotypes and was not likely to cause serious or widespread offence. Clearcast, which approves or rejects ads for broadcast on television, said the ad did not perpetuate negative racial stereotypes and instead demonstrated the product's inclusivity. The agency said one model with darker skin was depicted in a 'stylised and unrealistic way' to demonstrate dryness, but her skin tone was otherwise not a focal point. A second model, also with darker skin, was shown with itchy skin, but this was portrayed through scratching visibly healthy skin and the resulting marks, and was therefore more about sensation than any visible skin condition. The ASA said the use of different skin colours was a means of portraying a 'before and after' of the product's use, which created a juxtaposition of black skin shown as itchy, dry and cracked in the 'before' scenes, and white skin shown as smoother skin in the 'after' scenes. The watchdog said: 'The ad was therefore structured in such a way that it was the black skin, depicted in association with itchy and dry skin, which was shown to be problematic and uncomfortable, whereas the white skin, depicted as smoother and clean after using the product, was shown successfully changed and resolved. 'We considered that could be interpreted as suggesting that white skin was superior to black skin.' The ASA added: 'Although we understood that this message was not the one intended and might appear coincidental or pass unnoticed by some viewers, we considered that the ad was likely to reinforce the negative and offensive racial stereotype that black skin was problematic and that white skin was superior. 'We concluded that the ad included a racial stereotype and was therefore likely to cause serious offence.' It further told Colgate-Palmolive 'to ensure they avoided causing serious offence on the grounds of race'.


The Independent
7 minutes ago
- The Independent
Diabetes patients could be offered weight loss jabs sooner in major shake-up
People with type 2 diabetes in England could be offered treatments, including weight loss jabs, sooner in the biggest shake-up of care in a decade. New draft guidance from the National Institute for Health and Care Excellence (Nice) recommends a shift from a one-size-fits-all approach of starting everyone on the same medication to more personalised care that aims to prevent complications like heart failure and heart attacks. Newer type 2 diabetes drugs, known as SGLT-2 inhibitors, would be made a first-line treatment option in a move that could eventually help save tens of thousands of lives. SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are once-a-day tablets that reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. However, analysis by Nice found these drugs are under-prescribed. The new guidelines recommend patients who cannot tolerate metformin – the first-choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own. The decision comes after evidence suggested these drugs protect the heart and kidneys as well as control blood sugar, Nice said. It is estimated that the change could save almost 22,000 lives once uptake reaches 90 per cent of the population. Nice also suggests some groups of patients would also benefit from GLP-1 receptor agonists such as liraglutide or semaglutide sooner, rather than keeping them for the later stages of treatment. Semaglutide, sold under the brand name Ozempic, is licensed in the UK to treat type 2 diabetes, while its other brand – Wegovy – is also used by the NHS to help obese people lose weight. Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, said: 'This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health. This represents a significant evolution in how we approach type 2 diabetes treatment. 'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes and other serious complications before they occur. 'This is particularly important given that cardiovascular disease is the leading cause of death in people with type 2 diabetes.' Around 4.6 million people in the UK are living with diabetes, with nine in 10 of those having type 2. However, it is estimated that a further 1.3 million people may have undiagnosed type 2 diabetes. Nice analysed the records of 590,000 people and found SGLT-2 inhibitors are under-prescribed, particularly to women, older people, and black patients. Prof Benger added: 'The evidence from our analysis is clear. There are prescribing gaps that need to be addressed. 'The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications.' Dr Waqaar Shah, chairman of the guideline committee, added: 'We know that SGLT-2 inhibitors are currently under-prescribed, and our health economics analysis shows that people living in the most deprived areas would particularly benefit from universal access to these treatments. 'These recommendations could help reduce health inequalities while providing better outcomes for everyone.' Elsewhere, the draft guidance suggests different treatments for diabetes patients with certain characteristics or health conditions. These include adults with cardiovascular disease, who should be offered a triple therapy including a GLP-1 receptor agonist. Meanwhile, adults diagnosed with type 2 diabetes before 40 should be offered dual therapy before a GLP-1 receptor agonist is considered, while patients with chronic kidney disease should have tailored recommendations based on their kidney function. A public consultation on the new Nice guidelines is open until October 2. Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century. 'Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. 'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. 'Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. 'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'